These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 25576458)

  • 1. Prospectively recorded and MedDRA-coded safety data of intravenous methylprednisolone therapy in Graves' orbitopathy.
    Riedl M; Kolbe E; Kampmann E; Krämer I; Kahaly GJ
    J Endocrinol Invest; 2015 Feb; 38(2):177-82. PubMed ID: 25576458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective, systematically recorded mycophenolate safety data in Graves' orbitopathy.
    Riedl M; Kuhn A; Krämer I; Kolbe E; Kahaly GJ
    J Endocrinol Invest; 2016 Jun; 39(6):687-94. PubMed ID: 26886940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy.
    Bartalena L; Krassas GE; Wiersinga W; Marcocci C; Salvi M; Daumerie C; Bournaud C; Stahl M; Sassi L; Veronesi G; Azzolini C; Boboridis KG; Mourits MP; Soeters MR; Baldeschi L; Nardi M; Currò N; Boschi A; Bernard M; von Arx G;
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4454-63. PubMed ID: 23038682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is high dose intravenous methylprednisolone pulse therapy in patients with Graves' orbitopathy safe?
    Miśkiewicz P; Kryczka A; Ambroziak U; Rutkowska B; Główczyńska R; Opolski G; Kahaly G; Bednarczuk T
    Endokrynol Pol; 2014; 65(5):402-13. PubMed ID: 25301492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy.
    Currò N; Covelli D; Vannucchi G; Campi I; Pirola G; Simonetta S; Dazzi D; Guastella C; Pignataro L; Beck-Peccoz P; Ratiglia R; Salvi M
    Thyroid; 2014 May; 24(5):897-905. PubMed ID: 24417307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of two different regimens of intravenous methylprednisolone for patients with moderate to severe and active Graves' ophthalmopathy: a prospective, randomized controlled trial.
    He Y; Mu K; Liu R; Zhang J; Xiang N
    Endocr J; 2017 Feb; 64(2):141-149. PubMed ID: 27853049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucocorticoid-induced adrenal insufficiency after therapy with intravenous methylprednisolone in patients with moderate-to-severe and active Graves' orbitopathy: assessment with a low-dose corticotropin test.
    Pelewicz K; Miśkiewicz P
    J Endocrinol Invest; 2024 Aug; 47(8):1987-1994. PubMed ID: 38310626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.
    Kahaly GJ; Riedl M; König J; Pitz S; Ponto K; Diana T; Kampmann E; Kolbe E; Eckstein A; Moeller LC; Führer D; Salvi M; Curro N; Campi I; Covelli D; Leo M; Marinò M; Menconi F; Marcocci C; Bartalena L; Perros P; Wiersinga WM;
    Lancet Diabetes Endocrinol; 2018 Apr; 6(4):287-298. PubMed ID: 29396246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.
    Vannucchi G; Covelli D; Campi I; Origo D; Currò N; Cirello V; Dazzi D; Beck-Peccoz P; Salvi M
    Eur J Endocrinol; 2014 Jan; 170(1):55-61. PubMed ID: 24128430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall safety and efficacy of high-dose and low-dose intravenous glucocorticoid therapy in patients with moderate-to-severe active Graves' ophthalmopathy.
    Ueda-Sakane Y; Kanamoto N; Fushimi Y; Tanaka-Mizuno S; Yasuno S; Miura M; Sone M; Yasoda A; Okada T; Togashi K; Nakao K; Inagaki N
    Endocr J; 2016 Aug; 63(8):703-14. PubMed ID: 27263854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of Graves' orbitopathy treatment with intravenous glucocorticoids on adrenal function.
    Ambroziak U; Bluszcz G; Bednarczuk T; Miśkiewicz P
    Endokrynol Pol; 2017; 68(4):430-433. PubMed ID: 28604944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of combined parenteral and oral steroid therapy in Graves' orbitopathy.
    Nedeljkovic Beleslin B; Ciric J; Zarkovic M; Stojkovic M; Savic S; Knezevic M; Stankovic B; Trbojevic B
    Hormones (Athens); 2014; 13(2):222-8. PubMed ID: 24776622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: a questionnaire survey among members of the European Thyroid Association.
    Marcocci C; Watt T; Altea MA; Rasmussen AK; Feldt-Rasmussen U; Orgiazzi J; Bartalena L;
    Eur J Endocrinol; 2012 Feb; 166(2):247-53. PubMed ID: 22058081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of systemic steroid therapy in Graves' orbitopathy on regulatory T cells and Th17/Treg ratio.
    Siomkajło M; Mizera Ł; Szymczak D; Kolačkov K; Grzegrzółka J; Bolanowski M; Daroszewski J
    J Endocrinol Invest; 2021 Nov; 44(11):2475-2484. PubMed ID: 33866536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of combined orbital radiation and systemic steroids in the management of Graves' orbitopathy.
    Kim JW; Han SH; Son BJ; Rim TH; Keum KC; Yoon JS
    Graefes Arch Clin Exp Ophthalmol; 2016 May; 254(5):991-8. PubMed ID: 26876240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of non-standard regimen of systemic steroid therapy in patients with Graves' orbitopathy: a single-centre experience.
    Sawicka-Gutaj N; Gruszczyński D; Zawalna N; Nijakowski K; Skiba A; Pochylski M; Sowiński J; Ruchała M
    Pharmacol Rep; 2024 Feb; 76(1):185-194. PubMed ID: 38273183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute liver damage following intravenous glucocorticoid treatment for Graves' ophthalmopathy.
    Moleti M; Giuffrida G; Sturniolo G; Squadrito G; Campennì A; Morelli S; Puxeddu E; Sisti E; Trimarchi F; Vermiglio F; Marinò M
    Endocrine; 2016 Oct; 54(1):259-268. PubMed ID: 27003434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy Profile and Safety of Very Low-Dose Rituximab in Patients with Graves' Orbitopathy.
    Vannucchi G; Campi I; Covelli D; Currò N; Lazzaroni E; Palomba A; Soranna D; Zambon A; Fugazzola L; Muller I; Guastella C; Salvi M
    Thyroid; 2021 May; 31(5):821-828. PubMed ID: 33234032
    [No Abstract]   [Full Text] [Related]  

  • 19. Blood Pressure Profile and N-Terminal-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy.
    Miskiewicz P; Milczarek-Banach J; Bednarczuk T; Opolski G; Glowczynska R
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30261581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Graves' ophthalmopathy with high-dose intravenous methylprednisolone: a comparison of two dosing regimens.
    Sánchez-Ortiga R; Moreno-Pérez O; González Sánchez V; Arias Mendoza N; Mauri Dot M; Alfayate Guerra R; López Macia A; Picó Alfonso A
    Endocrinol Nutr; 2009 Mar; 56(3):118-22. PubMed ID: 19627724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.